Prostate CancerPROSCARDIONCT03776045
PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO)
A study of Prostate Cancer, run by University of East Anglia.
Trial summary
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy. Half of recruited participants completed a 3-month exercise intervention, while the other half did not perform any supervised exercise. Read more about this study
- Who is it for?
- Ages 50 to 80 years, men only
- Conditions the study is for
- Prostate Cancer
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 12 Aug 2013to 3 Feb 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male
- Aged 50 to 80 years
- Histologically confirmed stage I-IV prostate cancer
- Scheduled for treatment with a luteinizing hormone-releasing hormone (LHRH) agonist either alone or combined with radiotherapy
- Anticipated to remain on androgen deprivation therapy (ADT) for at least the next 6 months
- Willing and able to give written informed consent.
- Understand written and verbal instructions in English
- World Health Organisation (WHO) performance status 0 to 1
Who cannot join
- Previously treated with ADT
- Diagnosed or suspected metastatic bone disease
- Absolute contraindications to exercise testing and training as defined by the American College of Sports Medicine (ACSM, 2010)
- Prior myocardial infarction or heart failure
- Chronic obstructive pulmonary disease (COPD)
- Poorly controlled hypertension (≥ 200/110 mmHg)
Show all 9Show fewer
- Uncontrolled supraventricular tachycardia (≥ 100 bpm)
- Pre-existing severe musculoskeletal, neurological or psychiatric condition that may affect their ability to complete the testing battery or exercise training, as determined by the patient's physician
- Involvement in any other clinical trial or exercise trial
About this study
Official title: Effects of Exercise in Prostate Cancer Patients Initiating Androgen Deprivation Therapy: A Randomised Controlled Trial
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy. Half of recruited participants completed a 3-month exercise intervention, while the other half did not perform any supervised exercise. It was anticipated that exercise would have a positive effect on body composition, cardiorespiratory fitness and quality of life.
Read the detailed description
Androgen deprivation therapy (ADT) is routinely used as first-line treatment for locally advanced and metastatic prostate cancer. However, it is associated with many side effects such as increased fat mass and reduced skeletal muscle mass, cardiorespiratory fitness and metabolic health. Ultimately, these negative changes induced by ADT contribute to reduced health-related quality of life (HRQoL). This study evaluates whether 3-months of exercise can mitigate treatment toxicity in prostate cancer patients initiating ADT.
In a parallel groups, prospective, randomised controlled design, participants were randomly allocated to a standard care control group or standard care plus exercise group. The exercise group completed 3-months of combined aerobic and resistance training. The standard care group did not receive any supervised exercise or specific physical activity recommendations. Outcomes were assessed at baseline, 3-month (post-intervention), and 6-month (follow-up) endpoints.
- Conditions
- Prostate Cancer
- Being tested
- Standard care plus exercise
- Keywords
- Prostate Cancer, Androgen deprivation therapy, Exercise
- Medical subject headings
- Prostatic Neoplasms, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard care plus exerciseOther
The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted ~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
| Study group | Role | What they receive |
|---|---|---|
| Standard care | No intervention | This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study. |
| Standard care plus exercise | Experimental | This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy. Receives: Other: Standard care plus exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Whole body fat mass (kg)
Whole body fat mass was measured with bioelectrical impedance analysis (BIA) and concurrent bioelectrical impedance vector analysis (BIVA) with a single-frequency, phase-sensitive 50 kilohertz bioelectrical impedance analyzer (BIA-101, RJL/Akern Systems, Florence, Italy). This was chosen as the primary outcome because adiposity has shown a high propensity to increase during the initial phases of androgen deprivation therapy, more so than other measures (Galvao et al. 2011), which highlights the importance of targeting body fat at this stage of treatment.
Measured: Adjusted mean difference between groups at 3-month endpoint
Secondary outcomes (25)
Whole body fat mass (kg)
Whole body fat mass was measured with bioelectrical impedance analysis (BIA) and concurrent bioelectrical impedance vector analysis (BIVA) with a single-frequency, phase-sensitive 50 kilohertz bioelectrical impedance analyzer (BIA-101, RJL/Akern Systems, Florence, Italy). This was chosen as the primary outcome because adiposity has shown a high propensity to increase during the initial phases of androgen deprivation therapy, more so than other measures (Galvao et al. 2011), which highlights the importance of targeting body fat at this stage of treatment.
Measured: Adjusted mean difference between groups at 6-month endpoint
Whole body fat-free mass (kg)
Whole body fat-free mass was measured with bioelectrical impedance analysis (BIA) and concurrent bioelectrical impedance vector analysis (BIVA) with a single-frequency, phase-sensitive 50 kilohertz bioelectrical impedance analyzer (BIA-101, RJL/Akern Systems, Florence, Italy). This method is highly valid for measuring changes in body composition (Savastano et al. 2010).
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Anthropometric measurements (cm)
Waist, hip, mid-upper arm, forearm, mid-thigh and calf circumferences were measured with a non-stretching tape using standard techniques.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Peak oxygen consumption (VO2peak, ml/kg/min)
Determined as the highest oxygen consumption (V̇O2) attained during the cardiopulmonary exercise test
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Ventilatory anaerobic threshold (ml/kg/min)
Estimated using the modified V-slope method and confirmed by evaluating ventilatory equivalents and end-tidal pressures. Two analysts independently determined the ventilatory anaerobic threshold, with discrepancies of ≥ 7.5% resolved through discussion and consultation with a third analyst if necessary.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Ventilatory equivalents for O2 (V̇E/V̇O2) and CO2 (V̇E/V̇CO2)
Ratio of minute ventilation to O2 consumption and CO2 output at the ventilatory anaerobic threshold
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Oxygen pulse (ml/beat)
Ratio of oxygen consumption to heart rate at peak exercise during the cardiopulmonary exercise test
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Oxygen uptake efficiency slope (OUES)
Determined as the linear relationship between oxygen uptake and the logarithmic transformation of minute ventilation during the cardiopulmonary exercise test
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of cholesterol (mmol/L)
Concentrations of total cholesterol, low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) were measured from venous blood.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of triglycerides (mmol/L)
The concentration of triglycerides was measured from venous blood.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of testosterone (nmol/L)
Concentration of total testosterone was measured from venous blood.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of sex hormone binding globulin (nmol/L)
Concentration of sex hormone binding globulin was measured from venous blood.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
QRISK®2-2017 score
The percent risk of a cardiovascular disease event occurring in the next 10 years was calculated with QRISK®2-2017 Web Calculator (https://qrisk.org/2017). The total score ranges from 0 to 100 %, with higher scores indicating a greater risk of cardiovascular disease.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Gleason score
Gleason scores were measured from prostate biopsies. A score of 1 to 5 is assigned to the cells that make up the largest area of the tumor and another score of 1 to 5 is assigned to the cells that comprise the next largest area. A total Gleason score is then calculated by adding both of these scores together. Total scores ranged from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the least-differentiated tumors.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Prostate specific antigen (ng/mL)
Concentration of prostate specific antigen was measured from venous blood.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Skinfold thickness (mm)
Skinfold thickness was measured at suprailiac and subscapular sites with a skinfold caliper (Harpenden Skinfold Caliper, Baty International, Sussex, UK).
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Hand grip strength (kg)
Hand grip strength was measured with an analogue dynamometer (Takei Scientific Instruments Ltd., Tokyo, Japan).
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire (version 4)
Disease-specific health-related quality of life was assessed with the FACT-P 39-item questionnaire (version 4). Each item has a 5-point Likert-like response scale ranging from 0 ("Not at all") to 4 ("Very much"). A total score is calculated as the sum of each score from items 1 to 39, which can range from 0 to 156. Negatively worded items are reverse scored (subtracted from 4) prior to summing so that higher total scores indicate better health-related quality of life.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale (version 4)
Fatigue was assessed with the 13-item FACIT-Fatigue scale (version 4). Each item has a 5-point Likert-like response scale ranging from 0 ("Not at all") to 4 ("Very much"). A total score is calculated as the sum of each score from items 1 to 13, which can range from 0 to 52. Negatively worded items are reverse scored (subtracted from 4) prior to summing so that higher total scores indicate less experience of fatigue.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Godin Leisure-Time Exercise questionnaire
The Godin Leisure-Time Exercise questionnaire was used to characterise levels of physical activity. The questionnaire contains three items and asks the patient to recall the number of bouts of strenuous, moderate, or mild physical activity that exceed 15 min in duration in which they have engaged in over a typical week. A total score is calculated by multiplying the number of strenuous, moderate, and mild physical activity bouts by weights of 9, 5, and 3, respectively, and summing those values in an overall score that ranges from 0 to 119 in arbitrary units. Higher scores indicate participation in higher levels of physical activity.
Measured: Adjusted mean difference between groups at 3-month and 6-month endpoints
Number of recruited participants
Measured as the number of eligible participants who were eligible and consented to participate in the trial. This will be reported in a Consolidated Standards of Reporting Trials (CONSORT) participant flowchart.
Measured: Descriptive statistics reported during the two-year recruitment period
Number of adverse events
The number of adverse events were recorded to determine the feasibility of the exercise intervention. An adverse event was defined as the occurrence of any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the exercise intervention. The type of adverse events was also noted.
Measured: Descriptive statistics reported during the 3-month intervention period
Attrition rate
Established as the number of patients in the experimental group who discontinued the exercise intervention
Measured: Descriptive statistics reported during the 3-month intervention period.
Number of patients who were lost to follow-up
In the experimental group, patients lost to follow-up were characterised as those who completed the exercise intervention but did not complete endpoint testing. In the control group, patients lost to follow-up were the number of patients who did not complete endpoint testing.
Measured: Descriptive statistics reported at 3-month and 6-month endpoints
Average number of exercise sessions completed
The number of exercise sessions completed by each participant in the intervention group was recorded. These values were than averaged to provide a measure of adherence. The maximum number of exercise sessions that participants could complete was 24, so adherence ranged from 0 to 24 sessions, with higher scores indicating greater adherence.
Measured: Descriptive statistics reported during the 3-month intervention period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2018
- Study start12 Aug 2013
- Primary completion3 Feb 2016
- Study completion3 Feb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- After baseline measures were collected, participants were randomly allocated (1:1) to standard care or standard care plus exercise using a randomisation sequence created by an independent researcher (nQuery, Statistical Solutions, USA). Treatment allocation was concealed from the research team until after baseline measurements were collected.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of East Anglia
- Sponsor type
- University, hospital or other
- Collaborators
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Responsible party
- Sponsor
- Investigators
- John Saxton, Saxton, Study director, Northumbria UniversityWilphard Ndjavera, MD, Principal investigator, Norfolk and Norwich University Hospitals NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03776045
- Sponsor's protocol ID
- PROSCARDIO1992
- Acronym
- PROSCARDIO
- Status last verified
- Dec 2018
- First submitted
- 6 Dec 2018
- Last updated
- 14 Dec 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol. 2011 Oct;186(4):1291-7. doi: 10.1016/j.juro.2011.05.055. Epub 2011 Aug 17.
PubMed 21849187Savastano S, Belfiore A, Di Somma C, Mauriello C, Rossi A, Pizza G, De Rosa A, Prestieri G, Angrisani L, Colao A. Validity of bioelectrical impedance analysis to estimate body composition changes after bariatric surgery in premenopausal morbidly women. Obes Surg. 2010 Mar;20(3):332-9. doi: 10.1007/s11695-009-0006-5. Epub 2009 Oct 28.
PubMed 19862582
Study at a glance
From the registry record, last updated by the sponsor on 14 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Exercise in Prostate Cancer Patients Initiating Androgen Deprivation Therapy: A Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT03776045
- Acronym / sponsor ID
- PROSCARDIO / PROSCARDIO1992
- Conditions
- Prostate Cancer
- Keywords
- Prostate Cancer, Androgen deprivation therapy, Exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University of East AngliaUniversity, hospital or other
- Collaborators
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Study start
- 12 Aug 2013 (actual)
- Primary completion
- 3 Feb 2016 (actual)
- Study completion
- 3 Feb 2016 (actual)
- First posted
- 14 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy. Half of recruited participants completed a 3-month exercise intervention, while the other half did not perform any supervised exercise. It was anticipated that exercise would have a positive effect on body composition, cardiorespiratory fitness and quality of life.
Detailed description
Androgen deprivation therapy (ADT) is routinely used as first-line treatment for locally advanced and metastatic prostate cancer. However, it is associated with many side effects such as increased fat mass and reduced skeletal muscle mass, cardiorespiratory fitness and metabolic health. Ultimately, these negative changes induced by ADT contribute to reduced health-related quality of life (HRQoL). This study evaluates whether 3-months of exercise can mitigate treatment toxicity in prostate cancer patients initiating ADT.
In a parallel groups, prospective, randomised controlled design, participants were randomly allocated to a standard care control group or standard care plus exercise group. The exercise group completed 3-months of combined aerobic and resistance training. The standard care group did not receive any supervised exercise or specific physical activity recommendations. Outcomes were assessed at baseline, 3-month (post-intervention), and 6-month (follow-up) endpoints.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- After baseline measures were collected, participants were randomly allocated (1:1) to standard care or standard care plus exercise using a randomisation sequence created by an independent researcher (nQuery, Statistical Solutions, USA). Treatment allocation was concealed from the research team until after baseline measurements were collected.
| Arm | Type | Receives |
|---|---|---|
| Standard care | No intervention | –This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study. |
| Standard care plus exercise | Experimental | Other: Standard care plus exerciseThis group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Male
- Aged 50 to 80 years
- Histologically confirmed stage I-IV prostate cancer
- Scheduled for treatment with a luteinizing hormone-releasing hormone (LHRH) agonist either alone or combined with radiotherapy
- Anticipated to remain on androgen deprivation therapy (ADT) for at least the next 6 months
Key exclusion criteria (9 listed)
- Previously treated with ADT
- Diagnosed or suspected metastatic bone disease
- Absolute contraindications to exercise testing and training as defined by the American College of Sports Medicine (ACSM, 2010)
- Prior myocardial infarction or heart failure
- Chronic obstructive pulmonary disease (COPD)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard care plus exerciseThe exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted ~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training). | Other | Standard care plus exercise |
Primary outcome
Whole body fat mass (kg)
Time frame: Adjusted mean difference between groups at 3-month endpoint
Whole body fat mass was measured with bioelectrical impedance analysis (BIA) and concurrent bioelectrical impedance vector analysis (BIVA) with a single-frequency, phase-sensitive 50 kilohertz bioelectrical impedance analyzer (BIA-101, RJL/Akern Systems, Florence, Italy). This was chosen as the primary outcome because adiposity has shown a high propensity to increase during the initial phases of androgen deprivation therapy, more so than other measures (Galvao et al. 2011), which highlights the importance of targeting body fat at this stage of treatment.
25 secondary outcomes
Whole body fat mass (kg)
Time frame: Adjusted mean difference between groups at 6-month endpoint
Whole body fat-free mass (kg)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Anthropometric measurements (cm)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Peak oxygen consumption (VO2peak, ml/kg/min)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Ventilatory anaerobic threshold (ml/kg/min)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Ventilatory equivalents for O2 (V̇E/V̇O2) and CO2 (V̇E/V̇CO2)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Oxygen pulse (ml/beat)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Oxygen uptake efficiency slope (OUES)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of cholesterol (mmol/L)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of triglycerides (mmol/L)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of testosterone (nmol/L)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Concentration of sex hormone binding globulin (nmol/L)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
QRISK®2-2017 score
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Gleason score
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Prostate specific antigen (ng/mL)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Skinfold thickness (mm)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Hand grip strength (kg)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire (version 4)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale (version 4)
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Godin Leisure-Time Exercise questionnaire
Time frame: Adjusted mean difference between groups at 3-month and 6-month endpoints
Number of recruited participants
Time frame: Descriptive statistics reported during the two-year recruitment period
Number of adverse events
Time frame: Descriptive statistics reported during the 3-month intervention period
Attrition rate
Time frame: Descriptive statistics reported during the 3-month intervention period.
Number of patients who were lost to follow-up
Time frame: Descriptive statistics reported at 3-month and 6-month endpoints
Average number of exercise sessions completed
Time frame: Descriptive statistics reported during the 3-month intervention period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Dec 2018.
- Background: PubMed 21849187Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol. 2011 Oct;186(4):1291-7. doi: 10.1016/j.juro.2011.05.055. Epub 2011 Aug 17.
- Background: PubMed 19862582Savastano S, Belfiore A, Di Somma C, Mauriello C, Rossi A, Pizza G, De Rosa A, Prestieri G, Angrisani L, Colao A. Validity of bioelectrical impedance analysis to estimate body composition changes after bariatric surgery in premenopausal morbidly women. Obes Surg. 2010 Mar;20(3):332-9. doi: 10.1007/s11695-009-0006-5. Epub 2009 Oct 28.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Saxton, Saxton study director
Northumbria University
Wilphard Ndjavera, MD principal investigator
Norfolk and Norwich University Hospitals NHS Foundation Trust
Questions about this trial
What is this clinical trial studying?
A study of Prostate Cancer, run by University of East Anglia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Whole body fat mass (kg) (time frame: Adjusted mean difference between groups at 3-month endpoint). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03776045, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2018.